Market Overview
Size, scope, and category logic
- Brevintel analysis places consumer-facing EPA and DHA finished products at $55.4B in 2025, while fish oil concentration and refinement generated USD 2.6 billion in 2025 and is projected to reach $5B by 2035 at 6.8% CAGR (2026–2035).
- The market covers the value-added stage between crude marine oil and formulated end use: concentrating EPA and DHA, removing unwanted fractions, and delivering standardized ingredients.
- BASF SE led with over 14% market share in 2025; the top five—BASF SE (Pronova), dsm-firmenich, Epax Norway AS, KD Pharma Group SA, and Golden Omega—collectively held 50%.
- Global EPA and DHA ingredient volume reached about 136,000 metric tons in 2025, up 2.6% year over year, with ingredient market value near USD 2.53 billion after prices eased from the 2023–2024 supply shock.
- Concentration suppliers monetize verified composition, oxidation control, documentation, and format fit rather than crude-oil tonnage alone.
- End uses span dietary supplements, prescription products, clinical nutrition, food fortification, infant formula, aquaculture, and pet nutrition.
- Historic analysis covers 2022–2025 with 2025 as the base year; the forecast period is 2026–2035 across technology, form, application, and source species.
- Industry data suggests quality-led expansion remains constrained by marine-oil availability even as demand shifts toward regulated and premium concentrates.
Feedstock availability and processing economics
- Peru typically supplies roughly 25–33% of global fish oil through its north-central anchoveta fishery, making conversion yield and procurement discipline central to growth.
- The 2023 El Niño disrupted that base: Peruvian catches across two seasons fell to around 1.885 million tonnes, and global fish oil output declined about 21%.
- Production recovered partly in 2024, with global output up approximately 12% as Peruvian north-centre quotas were substantially fulfilled, though Chile and Northern Europe limited the offset.
- Output rose about 5% in the first ten months of 2025, but juvenile incidence and environmental stress again constrained Peru’s first season.
- High-purity output requires validated processing, analytical control, and documentation that are difficult to recreate after a supply disruption.
- KD Pharma’s October 2024 acquisition of dsm-firmenich’s marine-lipids business combined large-volume supply infrastructure with high-concentration capability.
- A rising commodity fish-oil price may lift nominal ingredient revenue while narrowing margins for processors unable to pass through costs or protect supply.
- Brevintel analysis finds integrated platforms better able to direct scarce material toward the most demanding applications than single-format suppliers.
Market Dynamics
Growth drivers
- Pharmaceutical and clinical nutrition demand is more resilient than supplement promotions because it depends on prescribed formulations, batch specifications, and documented quality systems.
- That application generated USD 423.1 million in 2025 and is forecast to grow at approximately 7.8% CAGR to USD 895.1 million by 2035.
- EU Commission Delegated Regulation (EU) 2016/127 requires DHA in infant formula placed on the EU market, effective from February 2020.
- China’s GB 10765-2021 revision triggered reformulation; 592 formulas from 97 companies were approved under the updated framework in 2023.
- Infant and maternal nutrition is forecast to expand from USD 231.3 million in 2025 at approximately 6.9% CAGR.
- rTG requires enzymatic re-esterification after concentration and is positioned around absorption performance; it is forecast to grow about 8.3% annually.
- Enzymatic processing is expected to grow about 9.2%, supporting rTG and free-fatty-acid forms that command differentiated price positions.
- Supercritical CO₂ fractionation under relatively low-temperature conditions helps target higher-concentration products when feedstock characteristics change.
Restraints and strategic boundaries
- Peru’s 25–33% contribution to global crude fish oil means quota decisions and ocean conditions can change raw-material availability faster than downstream demand adjusts.
- Chile, Iceland, and Norway add supply diversity, but their scale does not fully substitute for a material Peruvian shortfall.
- Entry into pharmaceutical-grade or advanced rTG supply requires quality systems, analytical testing, and documentation beyond a distillation unit alone.
- GC Rieber VivoMega completed a USD 75 million expansion in 2024, while Epax announced a USD 10 million Aalesund investment in 2025.
- Capital intensity protects established operators and slows industry-wide capacity response to demand spikes.
- Formula mandates turn DHA sourcing into a compliance task, reducing volatility for qualified concentrate even when discretionary supplement purchasing softens.
- Brevintel analysis finds the best-positioned firms pair qualification depth with procurement resilience across species, by-product streams, and formats.
- Processors can improve conversion efficiency but cannot manufacture a Peruvian fishing season, so feedstock optionality remains a structural advantage.
Segmentation Analysis
By concentration and refinement technology
- Molecular distillation is the revenue anchor, accounting for USD 1,306.7 million in 2025 and projected to reach USD 2,337.3 million by 2035.
- Its position reflects broad industrial applicability as a repeatable concentration base for subsequent processing steps.
- Wiped-film distillation, valued at USD 482.4 million in 2025, is forecast to outgrow short-path distillation in higher-throughput configurations.
- BASF’s PronovaPure portfolio specifies EPA and DHA concentrates to USP 40 and Ph.Eur. 10.0, underscoring distillation’s pharmaceutical relevance.
- Enzymatic processing is forecast to expand at approximately 9.2% CAGR, from USD 415.2 million in 2025 to USD 994.6 million by 2035.
- KD Pharma’s kd-pür platform combines multi-step distillation with supercritical CO₂ chromatography and offers EE, rTG, and FFA formats up to 99% EPA/DHA.
- Supercritical fluid extraction stood at USD 160.1 million in 2025, and membrane filtration at USD 134.4 million, for fractionation or finishing needs.
- Urea complexation and winterization remain relevant to mid-concentration and food-oriented supply, but grow more slowly with less differentiation.
By output product form
- EE remains the largest form at USD 1,395.7 million in 2025 as an established distillation output and pharmaceutical intermediate.
- Its projected 6.4% CAGR trails premium formats, while ultra-high or pharmaceutical-grade EE is forecast to grow approximately 8.2%.
- rTG is forecast to rise from USD 537.7 million in 2025 to USD 1,193.5 million by 2035 on absorption-led premium positioning.
- Epax states that its TGN line guarantees at least 90% rTG, versus an industry minimum cited at 50%.
- Phospholipids are forecast as the fastest-growing output form at approximately 9.5% CAGR, supported by differentiated marine-lipid delivery systems.
- The mix shift raises the importance of controlling oxidation, sensory performance, and stability through the entire conversion process.
- Specification and regulatory suitability still create a high-value EE tier rather than a uniformly commoditized category.
- Industry data suggests incremental value increasingly accrues after the initial concentration step via enzymatic and phospholipid formats.
By application and source species
- Dietary supplements and nutraceuticals are the largest application, with USD 1,144.6 million in 2025 and a projected 6.5% CAGR.
- Cardiovascular health is the largest supplement sub-application, while cognitive and brain-health use is projected to grow faster.
- Pharmaceuticals and clinical nutrition grow at approximately 7.8%, reflecting contractual quality and testing requirements.
- Food and beverage fortification was valued at USD 314.3 million in 2025; infant and maternal nutrition reached USD 231.3 million.
- Animal feed and aquaculture reached USD 205.6 million, linking concentrates to feed fatty-acid profiles with different pricing logic.
- Anchovy and anchoveta remain the largest source category at USD 964.7 million in 2025, reflecting high oil yield and Peru’s processing scale.
- Sardine, pilchard, and mackerel support European and Chinese supply chains, while herring remains important to Norway and Iceland.
- Salmonids and tuna are forecast to grow faster than the market average via aquaculture trimmings and canning by-products outside the pelagic seasonal window.
Regional Outlook
Europe and North America
- Europe is the largest regional market, generating approximately USD 791 million in 2025 and forecast to expand at approximately 6.6% CAGR.
- Norway is the region’s processing center, with BASF, Epax, and GC Rieber VivoMega operating high-specification marine-lipid capacity.
- Germany and France each represented about USD 128.5 million in 2025, while Italy and Spain each represented about USD 102.8 million.
- EU formula DHA rules support regional demand for qualified ingredients; the United Kingdom’s approximately 5.0% growth trails the regional rate.
- North America generated approximately USD 739.4 million in 2025, with the United States accounting for USD 636.6 million.
- U.S. fish-oil supplement sales volume increased 10% in 2024, according to SPINS data cited with Epax’s investment announcement.
- Canada contributes consumption and manufacturing relevance via KD Pharma’s Mulgrave, Nova Scotia facility within its high-concentration platform.
- Europe’s importance rests on both consumption and its ability to supply premium and pharmaceutical-grade concentrate globally.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is the fastest-growing region, generating approximately USD 706 million in 2025 and expanding at approximately 7.5% CAGR.
- China, at USD 262.9 million, combines supplement demand, infant-formula compliance, and domestic processing by KinOmega Biopharm and Sinomega.
- India, at USD 134.4 million, is forecast to grow about 8.3%, supported by expanding nutraceutical and pharmaceutical activity.
- Japan is a mature, high-specification market; GC Rieber VivoMega’s arrangement with Freemen Nutra highlights local commercialization partners.
- Latin America generated approximately USD 179.9 million in 2025, with Brazil and Mexico at roughly USD 77.1 million and USD 51.4 million.
- Peru’s crude-oil role and Chile’s Golden Omega capacity give the region upstream influence exceeding its finished-concentrate consumption.
- The Middle East and Africa generated approximately USD 154.2 million in 2025, led by Saudi Arabia and the UAE, with South Africa as a distribution gateway.
- Brevintel analysis finds regional demand and high-specification production capability remain separated, preserving export openings for qualified processors.
Competitive Landscape
Structure and recent moves
- Competition is segmented by quality tier, process breadth, and feedstock access rather than by one uniform market-share contest.
- BASF SE supplies PronovaPure and Maxomega EPA/DHA concentrates with USP 40 and Ph.Eur. 10.0 specifications.
- KD Pharma strengthened scale through the dsm-firmenich marine-lipids acquisition, including MEG-3 and facilities in Piura and Mulgrave.
- Epax competes in high-purity rTG and specialty lipids; its April 2025 EPAX Evolve 05 launch extended the portfolio into VLC-PUFA concentrates.
- GC Rieber VivoMega completed its expanded Kristiansund campus in 2024 (USD 75 million) and introduced VivoTech and VivoSure quality technologies.
- Epax announced a USD 10 million Aalesund investment targeting omega-9 and omega-11 extraction with early-2026 commissioning.
- Aker BioMarine broadened beyond krill with Revervia, a vegan algal DHA ingredient, and PL+ phospholipid innovation.
- Premium customers procure reproducibility, shelf-life assurance, and regulatory support as part of the ingredient, not as optional services.
Integrated producers
- BASF SE (Pronova)
- KD Pharma Group SA
- dsm-firmenich
- GC Rieber VivoMega AS
Specialty suppliers
- Epax Norway AS
- Golden Omega
- Polaris
- OLVEA Fish Oils
- Lysi hf
- Croda International
- Wiley Companies/AlaskOmega
- Aker BioMarine Antarctic AS
- Nissui Pharmaceutical Co., Ltd.
- KinOmega Biopharm
- Sinomega Biotech Engineering Co., Ltd.